Skip to main content
Top
Published in: European Journal of Epidemiology 8/2012

01-08-2012 | INFECTIOUS DISEASES

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy

Authors: Laura Galli, Stefania Salpietro, Gabriele Pellicciotta, Alberto Galliani, Piermarco Piatti, Hamid Hasson, Monica Guffanti, Nicola Gianotti, Alba Bigoloni, Adriano Lazzarin, Antonella Castagna

Published in: European Journal of Epidemiology | Issue 8/2012

Login to get access

Abstract

Type 2 diabetes mellitus is a growing problem in HIV population and a comparison with the general population may help screening and prevention. In this cross-sectional study the authors determined the prevalence of type 2 diabetes mellitus in 4,249 HIV-infected subjects attending the San Raffaele Infectious Diseases Department compared with 9,148 healthy controls recruited in 15 Italian regions, and identified risk factors associated with of type 2 diabetes mellitus. Type 2 diabetes mellitus was defined as reported diabetes, a fasting plasma glucose concentration ≥7.0 mmol/l, or current use of anti-diabetic medication. Prevalence of type 2 diabetes mellitus was higher in HIV-infected than healthy subjects (4.1 vs. 2.5 %; P < 0.0001). At multivariable analysis, HIV-infected subjects (odds ratio 1.70, 95 % CI, 1.12–2.51; P = 0.009), older age (P < 0.0001), higher BMI (P < 0.0001) and hypertension (P = 0.039) were associated with a higher risk of diabetes. Among HIV-infected patients, the risk of type 2 diabetes mellitus increased with older age (P < 0.0001), higher BMI (P = 0.003), higher triglycerides (P = 0.015) lower total cholesterol (P = 0.008), longer duration of HIV infection (P = 0.036) lower nadir CD4 (P = 0.027). Prevalence of type 2 diabetes mellitus in HIV-infected subjects was almost two-fold increased than healthy subjects and it was associated with the typical risk factors of the general population and also to longer duration of HIV infection and lower nadir CD4.
Literature
1.
go back to reference Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.PubMedCrossRef Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12.PubMedCrossRef
2.
go back to reference Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–84.PubMedCrossRef Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–84.PubMedCrossRef
3.
go back to reference Kourtis AP, Bansil P, Kahn HS, Posner SF, Jamieson DJ. Diabetes trends in hospitalized HIV-infected persons in the United States, 1994–2004. Curr HIV Res. 2009;7:481–6.PubMedCrossRef Kourtis AP, Bansil P, Kahn HS, Posner SF, Jamieson DJ. Diabetes trends in hospitalized HIV-infected persons in the United States, 1994–2004. Curr HIV Res. 2009;7:481–6.PubMedCrossRef
4.
go back to reference Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.PubMedCrossRef Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.PubMedCrossRef
5.
go back to reference Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805–11.PubMedCrossRef Worm SW, De Wit S, Weber R, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805–11.PubMedCrossRef
6.
go back to reference Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr. 2008;49(Suppl 2):S86–92.PubMed Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr. 2008;49(Suppl 2):S86–92.PubMed
7.
go back to reference Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64.PubMedCrossRef Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254–64.PubMedCrossRef
8.
go back to reference Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244–9.PubMedCrossRef Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010;33:2244–9.PubMedCrossRef
9.
go back to reference Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation. 2009;119:770–2.PubMedCrossRef Grinspoon S. Diabetes mellitus, cardiovascular risk, and HIV disease. Circulation. 2009;119:770–2.PubMedCrossRef
10.
go back to reference Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.PubMedCrossRef Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.PubMedCrossRef
11.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32 Suppl 1:S62–S67. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32 Suppl 1:S62–S67.
12.
go back to reference De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.PubMedCrossRef De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.PubMedCrossRef
13.
go back to reference Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr. 2007;45:66–71.PubMedCrossRef Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr. 2007;45:66–71.PubMedCrossRef
14.
go back to reference Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–601.PubMedCrossRef Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–601.PubMedCrossRef
15.
go back to reference Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–34.PubMedCrossRef Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–34.PubMedCrossRef
16.
go back to reference Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111–9.PubMedCrossRef Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007;45:111–9.PubMedCrossRef
17.
go back to reference Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445–53.PubMedCrossRef Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007;21:2445–53.PubMedCrossRef
18.
go back to reference Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92:1189–96.PubMedCrossRef Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92:1189–96.PubMedCrossRef
19.
go back to reference The InterAct Consortium. Mediterranean diet and type 2 diabetes risk in the European prospective investigation into cancer and nutrition (EPIC) study. Diabetes Care 2011;34:1913–1918. The InterAct Consortium. Mediterranean diet and type 2 diabetes risk in the European prospective investigation into cancer and nutrition (EPIC) study. Diabetes Care 2011;34:1913–1918.
20.
go back to reference Lumpkin MM. US Food Drug Administration public health advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Rockville, MD: US Food and Drug Administration; 1997. Lumpkin MM. US Food Drug Administration public health advisory: reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Rockville, MD: US Food and Drug Administration; 1997.
21.
go back to reference Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1: protease inhibitor-associated lipodystrophy, hyperlipidaemia and adiabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.PubMedCrossRef Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1: protease inhibitor-associated lipodystrophy, hyperlipidaemia and adiabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.PubMedCrossRef
22.
go back to reference Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.PubMedCrossRef Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302.PubMedCrossRef
23.
go back to reference Brambilla AM, Novati R, Calori G, et al. Stavudine- or indinavir-containing regimens are associated with an increate risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993–5.PubMedCrossRef Brambilla AM, Novati R, Calori G, et al. Stavudine- or indinavir-containing regimens are associated with an increate risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993–5.PubMedCrossRef
24.
go back to reference Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–83.PubMedCrossRef Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–83.PubMedCrossRef
25.
go back to reference Garcia-Benayas T, Rendon AL, Rodriguez-Novoa S, et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses. 2006;22:333–7.PubMedCrossRef Garcia-Benayas T, Rendon AL, Rodriguez-Novoa S, et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses. 2006;22:333–7.PubMedCrossRef
26.
go back to reference Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med. 2001;344:142–4.PubMed Modest GA, Fuller J. Abacavir and diabetes. N Engl J Med. 2001;344:142–4.PubMed
27.
go back to reference Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G. Socio-economic differences in the prevalence of diabetes in Italy: the population based Turin study. Nutr Metab Cardiovasc Dis. 2008;18:678–82.PubMedCrossRef Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G. Socio-economic differences in the prevalence of diabetes in Italy: the population based Turin study. Nutr Metab Cardiovasc Dis. 2008;18:678–82.PubMedCrossRef
Metadata
Title
Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy
Authors
Laura Galli
Stefania Salpietro
Gabriele Pellicciotta
Alberto Galliani
Piermarco Piatti
Hamid Hasson
Monica Guffanti
Nicola Gianotti
Alba Bigoloni
Adriano Lazzarin
Antonella Castagna
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 8/2012
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-012-9707-5

Other articles of this Issue 8/2012

European Journal of Epidemiology 8/2012 Go to the issue